Lytix Biopharma announces the publication of a paper describing how LTX-315 mediates antitumor activity through multiple pathways

21 Mar 2024 12:43 CET

Oslo, March 21, 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a
clinical stage immune-oncology company, today announces publication of a paper
that describes how LTX-315 treatment activates specific type of immune cells
that are critical for a proper priming of tumor-specific T cells. The paper
entitled “LTX-315 triggers anticancer immunity by inducing MyD88-dependent
maturation of dendritic cells” is published as an open access article in
Frontiers in Immunology, a high-profile journal covering research across basic,
translational and clinical immunology.

The study was a collaborative research effort between Lytix and the highly
reputed research groups of Dr Joost Oppenheim/Dr De Yang at National Cancer
Institute, Frederick, and Dr Lorenzo Galluzzi Lab at Weill Cornell Medicine, New
York, both in the U.S.A.

The paper describes how LTX-315 has multiple ways to activate specific immune
cells called tumor antigen presenting cells (APCs) and parts of the results were
presented at the world largest immuno-oncology conference in 2022, The Society
for Immunotherapy of Cancer’s Annual Meeting, (SITC 2022, Boston, U.S.A).

LTX-315 has been designed to kill cancer cells in a way that effectively expose
their tumor antigens. The data from this paper document that LTX-315 has an
additional anticancer effect by activating APCs (dendritic cells) that are
specialized to pick up tumor antigens and present them for the T cells. Through
this dual mode of action LTX-315 possess two mechanisms that both are critical
for boosting strong T cell responses.

“These data are very compelling and further explain how LTX-315 is able to
generate broad T cell responses in the majority of cancer patients. The findings
represent an important step towards realizing the full translational potential
of LTX-315 and further strengthen the position of LTX-315 as a potent anticancer
immunotherapeutic agent ideal to be combined with other types of
immunotherapies”, said Øystein Rekdal, CEO of Lytix Biopharma.

For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com


Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site